Kymera Therapeutics, Inc. Peer Comparison
Metric | Value | Ranking | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap | $2.4 Billion | 3/12 | RVMD $7.4B |
EWTX $2.4B |
KYMR $2.4B |
AGIO $1.9B |
NRIX $1.3B |
GLUE $416.5M |
ELYM $342.7M |
FHTX $340.9M |
CCCC $224.5M |
IPSC $65.5M |
STTK $63.5M |
PRLD $53.4M |
Gross Margin | 47% | 8/12 | NRIX 100% |
STTK 100% |
PRLD 100% |
GLUE 100% |
AGIO 91% |
FHTX 91% |
CCCC 87% |
KYMR 47% |
RVMD 0% |
EWTX 0% |
ELYM 0% |
IPSC -100% |
Profit Margin | -100% | 5/12 | AGIO 100% |
RVMD 0% |
EWTX 0% |
ELYM 0% |
KYMR -100% |
NRIX -100% |
STTK -100% |
CCCC -100% |
FHTX -100% |
PRLD -100% |
GLUE -100% |
IPSC -100% |
EBITDA margin | -1928% | 11/12 | RVMD -100% |
EWTX -100% |
ELYM -100% |
CCCC -184% |
GLUE -288% |
FHTX -305% |
NRIX -454% |
STTK -598% |
PRLD -1132% |
AGIO -1147% |
KYMR -1928% |
IPSC -3532% |
Quarterly Revenue | $3.7 Million | 6/12 | CCCC $15.4M |
NRIX $13.3M |
GLUE $9.2M |
AGIO $9.0M |
FHTX $7.8M |
KYMR $3.7M |
PRLD $3.0M |
STTK $3.0M |
IPSC $791,000 |
RVMD $0 |
EWTX $0 |
ELYM $0 |
Quarterly Earnings | -$62.5 Million | 11/12 | AGIO $947.9M |
STTK -$16.7M |
FHTX -$19.1M |
GLUE -$23.9M |
CCCC -$24.7M |
IPSC -$31.2M |
PRLD -$32.3M |
EWTX -$34.1M |
ELYM -$54.9M |
NRIX -$58.5M |
KYMR -$62.5M |
RVMD -$156.3M |
Quarterly Free Cash Flow | -$50.0 Million | 9/12 | ELYM -$667,000 |
STTK -$16.1M |
FHTX -$21.3M |
GLUE -$21.4M |
CCCC -$24.1M |
PRLD -$27.4M |
IPSC -$27.5M |
EWTX -$27.9M |
KYMR -$50.0M |
NRIX -$50.9M |
AGIO -$84.6M |
RVMD -$133.9M |
Trailing 4 Quarters Revenue | $87.6 Million | 1/12 | KYMR $87.6M |
NRIX $54.5M |
CCCC $33.7M |
AGIO $32.9M |
FHTX $25.5M |
GLUE $15.0M |
STTK $6.4M |
PRLD $3.0M |
IPSC $2.7M |
RVMD $0 |
EWTX $0 |
ELYM $0 |
Trailing 4 Quarters Earnings | -$167.5 Million | 10/12 | CCCC $15.4M |
NRIX $13.3M |
GLUE $9.2M |
AGIO $9.0M |
FHTX $7.8M |
KYMR $3.7M |
PRLD $3.0M |
STTK $3.0M |
IPSC $791,000 |
RVMD -$0 |
EWTX -$0 |
ELYM -$0 |
Quarterly Earnings Growth | -18% | 8/12 | AGIO 1138% |
STTK 39% |
GLUE 32% |
CCCC 31% |
RVMD 9% |
IPSC 5% |
PRLD 2% |
KYMR -18% |
FHTX -33% |
EWTX -33% |
NRIX -40% |
ELYM -952% |
Annual Earnings Growth | 1% | 8/12 | AGIO 297% |
CCCC 23% |
STTK 18% |
GLUE 15% |
FHTX 11% |
ELYM 6% |
IPSC 2% |
KYMR 1% |
PRLD -7% |
RVMD -16% |
NRIX -27% |
EWTX -38% |
Quarterly Revenue Growth | -21% | 10/12 | IPSC 434% |
STTK 337% |
AGIO 21% |
CCCC 0% |
PRLD 0% |
EWTX 0% |
GLUE 0% |
ELYM 0% |
NRIX -12% |
KYMR -21% |
FHTX -55% |
RVMD -100% |
Annual Revenue Growth | 61% | 4/12 | IPSC 503% |
STTK 400% |
CCCC 199% |
KYMR 61% |
AGIO 19% |
PRLD 0% |
EWTX 0% |
GLUE 0% |
ELYM 0% |
NRIX -23% |
FHTX -26% |
RVMD -100% |
Cash On Hand | $110.7 Million | 5/12 | AGIO $253.7M |
ELYM $223.1M |
RVMD $201.3M |
GLUE $125.6M |
KYMR $110.7M |
NRIX $110.0M |
CCCC $59.6M |
FHTX $57.7M |
IPSC $52.6M |
EWTX $44.8M |
STTK $43.8M |
PRLD $11.1M |
Short Term Debt | $12.9 Million | 2/12 | AGIO $16.3M |
KYMR $12.9M |
FHTX $8.8M |
RVMD $8.4M |
NRIX $8.0M |
CCCC $5.6M |
PRLD $5.4M |
IPSC $3.8M |
GLUE $3.6M |
EWTX $992,000 |
ELYM $100,000 |
STTK -$0 |
Long Term Debt | $75.4 Million | 3/12 | IPSC $101.7M |
RVMD $78.3M |
KYMR $75.4M |
CCCC $61.5M |
AGIO $44.5M |
GLUE $40.1M |
FHTX $30.3M |
NRIX $20.3M |
PRLD $15.4M |
EWTX $3.4M |
STTK $2.7M |
ELYM $0 |
PE | -1.00 | 2/12 | AGIO 2.82 |
KYMR -1.00 |
RVMD -1.00 |
NRIX -1.00 |
STTK -1.00 |
CCCC -1.00 |
FHTX -1.00 |
PRLD -1.00 |
EWTX -1.00 |
GLUE -1.00 |
ELYM -1.00 |
IPSC -1.00 |
PS | 27.28 | 3/12 | AGIO 57.90 |
GLUE 27.82 |
KYMR 27.28 |
NRIX 24.47 |
IPSC 24.38 |
PRLD 17.79 |
FHTX 13.36 |
STTK 9.87 |
CCCC 6.67 |
RVMD -1.00 |
EWTX -1.00 |
ELYM -1.00 |
PB | 2.67 | 3/12 | EWTX 4.92 |
RVMD 4.73 |
KYMR 2.67 |
NRIX 2.53 |
GLUE 2.03 |
ELYM 1.54 |
AGIO 1.17 |
CCCC 0.93 |
STTK 0.66 |
PRLD 0.34 |
IPSC 0.33 |
FHTX 0.00 |
PC | 21.57 | 3/12 | EWTX 53.66 |
RVMD 36.85 |
KYMR 21.57 |
NRIX 12.14 |
AGIO 7.50 |
FHTX 5.91 |
PRLD 4.79 |
CCCC 3.76 |
GLUE 3.32 |
ELYM 1.54 |
STTK 1.45 |
IPSC 1.24 |
Liabilities to Equity | 0.16 | 6/12 | IPSC 0.99 |
CCCC 0.55 |
GLUE 0.53 |
NRIX 0.27 |
PRLD 0.26 |
KYMR 0.16 |
STTK 0.16 |
RVMD 0.13 |
AGIO 0.10 |
EWTX 0.05 |
ELYM 0.02 |
FHTX 0.00 |
ROA | -0.16 | 2/12 | AGIO 38% | KYMR -16% | EWTX -24% | CCCC -28% | ELYM -28% | NRIX -29% | FHTX -30% | RVMD -31% | IPSC -33% | GLUE -38% | STTK -67% | PRLD -68% |
ROE | -0.19 | 3/12 | FHTX 322% |
AGIO 41% |
KYMR -19% |
EWTX -25% |
ELYM -29% |
RVMD -34% |
NRIX -37% |
CCCC -43% |
GLUE -58% |
IPSC -66% |
STTK -78% |
PRLD -85% |
Current Ratio | 7.29 | 6/12 | ELYM 60.42 |
EWTX 22.82 |
AGIO 10.85 |
RVMD 8.96 |
STTK 7.38 |
KYMR 7.29 |
PRLD 4.84 |
NRIX 4.70 |
GLUE 2.87 |
CCCC 2.82 |
IPSC 2.01 |
FHTX 0.92 |
Quick Ratio | 3.88 | 6/12 | AGIO 2.82 |
KYMR -1.00 |
RVMD -1.00 |
NRIX -1.00 |
STTK -1.00 |
CCCC -1.00 |
FHTX -1.00 |
PRLD -1.00 |
EWTX -1.00 |
GLUE -1.00 |
ELYM -1.00 |
IPSC -1.00 |
Long Term Debt to Equity | 0.08 | 5/12 | IPSC} 0.52 |
CCCC} 0.25 |
GLUE} 0.19 |
PRLD} 0.10 |
KYMR} 0.08 |
RVMD} 0.05 |
NRIX} 0.04 |
AGIO} 0.03 |
STTK} 0.03 |
EWTX} 0.01 |
ELYM} 0.00 |
FHTX} -1.07 |
Debt to Equity | 0.10 | 5/12 | CCCC 0.28 |
IPSC 0.26 |
GLUE 0.21 |
PRLD 0.12 |
KYMR 0.10 |
RVMD 0.06 |
NRIX 0.05 |
AGIO 0.04 |
STTK 0.03 |
EWTX 0.01 |
ELYM 0.00 |
FHTX -1.38 |
Burn Rate | 1.61 | 7/12 | GLUE 4.76 |
ELYM 4.06 |
STTK 2.61 |
FHTX 2.56 |
CCCC 2.09 |
NRIX 1.79 |
KYMR 1.61 |
IPSC 1.45 |
EWTX 1.30 |
RVMD 1.25 |
PRLD 0.33 |
AGIO -0.27 |
Cash to Cap | 0.05 | 10/12 | IPSC 0.80 |
STTK 0.69 |
ELYM 0.65 |
GLUE 0.30 |
CCCC 0.27 |
PRLD 0.21 |
FHTX 0.17 |
AGIO 0.13 |
NRIX 0.08 |
KYMR 0.05 |
RVMD 0.03 |
EWTX 0.02 |
CCR | 0.80 | 10/12 | FHTX 1.11 |
CCCC 0.98 |
STTK 0.97 |
GLUE 0.90 |
IPSC 0.88 |
NRIX 0.87 |
RVMD 0.86 |
PRLD 0.85 |
EWTX 0.82 |
KYMR 0.80 |
ELYM 0.01 |
AGIO -0.09 |
EV to EBITDA | -32.81 | 12/12 | RVMD} -1.00 |
EWTX} -1.00 |
ELYM} -1.00 |
STTK} -1.25 |
PRLD} -1.78 |
IPSC} -2.28 |
CCCC} -8.21 |
GLUE} -12.62 |
FHTX} -13.51 |
AGIO} -16.64 |
NRIX} -20.76 |
KYMR} -32.81 |
EV to Revenue | 27.02 | 2/12 | AGIO 52.04 |
KYMR 27.02 |
IPSC 23.73 |
NRIX 22.97 |
GLUE 22.35 |
PRLD 20.13 |
FHTX 12.63 |
CCCC 6.89 |
STTK 3.48 |
RVMD -1.00 |
EWTX -1.00 |
ELYM -1.00 |